Literature DB >> 22294403

Overview of mouse models of inflammatory bowel disease and their use in drug discovery.

Joseph R Maxwell1, Joanne L Viney.   

Abstract

Inflammatory bowel disease (IBD), a condition that affects millions of individuals, encompasses two distinct conditions: Crohn's disease (CD) and ulcerative colitis (UC). CD is an inflammatory condition affecting any part of the digestive tract between the mouth and anus, but, most commonly, the ileum and colon. It is distinguished by the presence of granulomas in the mucosal tissue and patchy areas of transmural inflammation. UC is restricted to the colon and is manifest as continuous inflammation starting from the rectum and extending back towards the cecum. Inflammation in UC is primarily restricted to mucosal layers. Research is ongoing to understand the causality of these two diseases, and advances in understanding of their pathology have resulted from the variety of mouse models of IBD that have emerged since the early 1990s. Described in this unit are contemporary mouse models of these conditions and examples of their use in drug discovery.

Entities:  

Mesh:

Year:  2009        PMID: 22294403     DOI: 10.1002/0471141755.ph0557s47

Source DB:  PubMed          Journal:  Curr Protoc Pharmacol        ISSN: 1934-8282


  6 in total

Review 1.  Pharmacological intervention studies using mouse models of the inflammatory bowel diseases: translating preclinical data into new drug therapies.

Authors:  Iurii Koboziev; Fridrik Karlsson; Songlin Zhang; Matthew B Grisham
Journal:  Inflamm Bowel Dis       Date:  2011-02-10       Impact factor: 5.325

2.  Intestinal Epithelial Cell Tyrosine Kinase 2 Transduces IL-22 Signals To Protect from Acute Colitis.

Authors:  Eva Hainzl; Silvia Stockinger; Isabella Rauch; Susanne Heider; David Berry; Caroline Lassnig; Clarissa Schwab; Felix Rosebrock; Gabriel Milinovich; Michaela Schlederer; Michael Wagner; Christa Schleper; Alexander Loy; Tim Urich; Lukas Kenner; Xiaonan Han; Thomas Decker; Birgit Strobl; Mathias Müller
Journal:  J Immunol       Date:  2015-10-02       Impact factor: 5.422

3.  Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis.

Authors:  Hilda Vargas Robles; Karla Fabiola Castro Ochoa; Porfirio Nava; Angélica Silva Olivares; Mineko Shibayama; Michael Schnoor
Journal:  J Vis Exp       Date:  2017-01-05       Impact factor: 1.355

4.  Evaluation of Quantitative Imaging Biomarkers in the DSS Colitis Model.

Authors:  Anne Beltzer; Thomas Kaulisch; Teresa Bluhmki; Tanja Schoenberger; Birgit Stierstorfer; Detlef Stiller
Journal:  Mol Imaging Biol       Date:  2016-10       Impact factor: 3.488

5.  DSS-induced colitis produces inflammation-induced bone loss while irisin treatment mitigates the inflammatory state in both gut and bone.

Authors:  Corinne E Metzger; S Anand Narayanan; Jon P Elizondo; Anne Michal Carter; David C Zawieja; Harry A Hogan; Susan A Bloomfield
Journal:  Sci Rep       Date:  2019-10-22       Impact factor: 4.379

6.  Micro-ecology restoration of colonic inflammation by in-Situ oral delivery of antibody-laden hydrogel microcapsules.

Authors:  Bo Li; Xin Li; Xiaodong Chu; Pengcheng Lou; Yin Yuan; Aoxiang Zhuge; Xueling Zhu; Yangfan Shen; Jinghua Pan; Liyuan Zhang; Lanjuan Li; Zhongwen Wu
Journal:  Bioact Mater       Date:  2021-12-25
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.